MarketVIEW Chronic Vaccines  ·  April 2025

Acne Vulgaris Therapeutic Vaccines
Commercial Forecast

The world's most common inflammatory skin disease. Profound psychosocial burden. Current treatments have major pitfalls. The vaccine industry is now entering this space - and this is the only independent commercial assessment of the opportunity.

10 Developed Markets Forecast to 2045 mRNA Pipeline Age & Gender Split Interactive Model
Product catalogue
VAMV034
Published April 2025

Format
PDF + Excel model
Presentation slides
>200 slides
Excel worksheets
120 sheets
Markets modelled
10 developed
Forecast horizon
To 2045
Model split
Age & gender
~9%
Global prevalence
(GBD data)
~90%
Adolescent
prevalence
10
Developed markets
modelled to 2045
2045
Longest-horizon
forecast in portfolio
Disease background

Why acne vulgaris is a serious unmet medical need

Acne is not a cosmetic inconvenience. It is a chronic inflammatory disease with significant morbidity, growing prevalence and current treatments that carry major pitfalls - creating a genuine medical case for a vaccine approach.

GBD data & peer-reviewed sources

Acne vulgaris - pathology and burden

Acne vulgaris is a chronic inflammatory disease and among the most common dermatological conditions worldwide, with a global prevalence of approximately ~9% (Global Burden of Disease). Acne predominantly affects adolescents, with a prevalence approaching ~90% in this age group, but it commonly persists into adulthood - particularly in women. Importantly, recent epidemiological data suggest that acne is becoming more prevalent, not less (Zhu Z et al., 2025).

In adolescents, approximately 20-35% of cases are classified as moderate-to-severe - the segment for which current treatments are most problematic. Existing therapies (topical retinoids, antibiotics, isotretinoin, hormonal agents) carry significant tolerability issues, antibiotic resistance concerns and, in the case of isotretinoin, serious teratogenicity risks. None achieve durable remission without continued use. Persistent acne has a profound effect on an individual's self-esteem and quality of life, resulting in significant psychosocial morbidity - including depression and anxiety - that is increasingly recognised in clinical guidelines.

The microbial driver of inflammatory acne is Cutibacterium acnes (formerly Propionibacterium acnes, C.acnes). Pathogenic strains trigger innate and adaptive immune responses within the pilosebaceous unit, driving the lesion cascade. A therapeutic vaccine targeting relevant C.acnes antigens could significantly reduce both inflammatory and non-inflammatory lesions - and unlike antibiotics, would not contribute to antimicrobial resistance. It could function as a monotherapy or as an adjunct to existing therapies, positioned in the moderate-to-severe segment where unmet need is highest.

~9%
Global prevalence - one of the top 10 most prevalent diseases worldwide
20-35%
Adolescent cases classified as moderate-to-severe - the key vaccine target segment
Rising
Prevalence is increasing, not decreasing - strengthening the long-term commercial case (Zhu et al., 2025)
R&D pipeline

The vaccine industry enters acne - led by Sanofi mRNA

The acne vaccine pipeline is early-stage but advancing. The entry of a major vaccine manufacturer with an mRNA platform is a significant signal. The commercial model is built around realistic assumptions for first-to-market scenarios given the current pipeline stage.

  • Sanofi PasteurmRNA
    SP0268 Phase 1/2
    mRNA-based C.acnes vaccine - the most advanced acne vaccine candidate globally and the first mRNA approach in this indication. Phase 1/2 currently in progress. Sanofi's entry into acne vaccinology is a landmark development, bringing substantial clinical development and commercial expertise to what was previously an academic research area. The VacZine Analytics model includes scenarios based on SP0268 progression timelines and potential positioning in moderate-to-severe adolescent and adult acne. In August 2026, Sanofi filed a dedicated Phase 1/2 safety study of SP0268 in adolescents aged 12-17 with moderate-to-severe acne (NCT07756957) - extending the clinical programme directly into the adolescent segment that anchors this report's commercial model.
  • Other approachesPreclinical
    Earlier-stage C.acnes vaccine programmes
    Several academic and smaller biotech programmes are targeting C.acnes antigens through protein subunit and killed whole-cell approaches. The report reviews the full preclinical landscape and assesses the probability and timing of additional entrants relative to Sanofi SP0268.
Scope of analysis

Six dimensions - one commercial picture

This is the only independent commercial forecast for acne vulgaris therapeutic vaccines. The model combines a rigorous disease and pipeline review with a fully interactive 10-market forecast model that allows buyers to test their own assumptions.

🌍
10-market commercial model

Developed-market volume and revenue forecasts across the USA, EU5 and other key markets. Outputs split by age group and gender - essential for a disease with markedly different prevalence profiles across demographics.

🧬
mRNA pipeline & platform analysis

Sanofi SP0268 assessed in depth - mechanism of action, Phase 1/2 data as it emerges, competitive positioning against current standard-of-care and likely payer positioning in the moderate-to-severe segment.

🔬
Epidemiology & treatment landscape

Up-to-date review of acne prevalence, severity distribution, treatment guidelines and current therapy limitations. GBD data updated to reflect rising prevalence trends. Positions the vaccine opportunity clearly within the unmet need gap.

📊
Scenario-based revenue forecasts

Two interactive scenario-based Excel workbooks covering different clinical development and market access assumptions. Users can adjust product administration schedule, uptake rates, coverage, pricing and acne severity targeting to generate their own scenarios.

💰
Pricing & uptake modelling

Detailed pricing rationale benchmarked against current acne therapies (isotretinoin courses, biologics, dermatologist-administered treatments). Uptake modelled separately for adolescent and adult populations, with sensitivity analysis.

🔭
Forecast horizon to 2045

The longest-horizon forecast in the VacZine Analytics portfolio - appropriate given the early pipeline stage and the time needed for clinical development, regulatory approval and market access. Captures the full commercial lifecycle of first-generation acne vaccines.

Sample analysis

A glimpse of the market model

The table below shows a partial view of the target segment framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Target segment Age group Gender split Severity Revenue scenario
Adolescent acne12-17 yrsM & F modelledModerate-to-severeModelled
Young adult acne18-29 yrsFemale weightedPersistent moderate+Modelled
Adult / late-onset30+ yrsPredominantly femaleModerate+Modelled
██████████████████████████████████$██m (base)
Total addressableAll agesAllModerate-severe$███m
🔒
Full model in the licensed workbook
10 markets · 2 scenario workbooks · uptake & pricing assumptions to 2045
Request access →
Deliverables

What you receive

A comprehensive intelligence package designed for decision-makers who need both the clinical context and the commercial numbers in a single, decision-ready format.

  • Executive presentation (>200 slides, PDF) - disease epidemiology, treatment landscape, C.acnes vaccinology, pipeline analysis and commercial assessment with full narrative and supporting references
  • Two scenario-based interactive Excel workbooks (120 worksheets) - 10-market volume and revenue outputs with toggleable assumptions for product administration, uptake, coverage, pricing and acne severity targeting
  • Age and gender-segmented forecasts - revenue outputs broken down by demographic group across the full forecast horizon to 2045
  • Pipeline analysis - Sanofi SP0268 mRNA programme assessed in depth alongside the preclinical landscape and competitive entry probability modelling
  • Treatment landscape review - current therapies (topicals, antibiotics, isotretinoin, hormonal, biologics), their limitations and the unmet need gap a vaccine would address
  • Pricing & market access analysis - benchmarked against dermatology analogues and biologic pricing precedents across US and European payer systems
Target audience

Built for organisations tracking the acne vaccine opportunity

The most valuable analysis in a pipeline this early is one that gives you the commercial framework before the data arrives - so you can act when it does.

💊

Vaccine & dermatology developers

Pipeline positioning, commercial feasibility and target population rationale for acne vaccine programmes at any development stage.

📈

Corporate strategy & BD

Validate the commercial opportunity size and competitive landscape before investing in acne vaccine development or in-licensing discussions.

🏦

Investors & analysts

Independent assessment of the acne vaccine market size, pipeline risk and timing for due diligence on dermatology and mRNA vaccine assets.

🔬

Academic & translational researchers

Commercial context for grant applications and translational development decisions involving C.acnes-targeting vaccine approaches.

📋

Market access & HEOR

Pricing benchmarks, payer landscape and value dossier context for a novel therapeutic vaccine indication in dermatology.

🏥

Dermatology KOLs & clinical teams

Understanding the commercial and regulatory development pathway for acne vaccines as the Sanofi Phase 1/2 data emerges.

About this analysis · VAMV034

The VacZine Analytics acne vulgaris report is the only independent commercial forecast for this indication. Published in April 2025, it was timed to coincide with the first major industry entrant - Sanofi Pasteur's SP0268 mRNA programme - entering Phase 1/2 trials. The model uses a 2045 forecast horizon, appropriate given the current early-stage pipeline and typical dermatology vaccine development timelines.

The interactive workbook design allows clients to stress-test pricing, uptake and scenario assumptions - making it a living commercial tool rather than a static report. It is one of the most visited pages in the VacZine Analytics portfolio, reflecting the high level of industry interest in this emerging space.

MarketVIEW · VAMV034 · Chronic Vaccines

License the acne vaccine commercial forecast

Contact VacZine Analytics for pricing, sample slides and licensing terms. Single-licence and multi-user options available.